posted
RTGI 014x015 -- good news today and good buying opp here.
EXTON, PA, Apr 23, 2007 (MARKET WIRE via COMTEX) -- Rheologics Technologies Inc. ("Rheologics" or the "Company") (PINKSHEETS: RTGI), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announces plans for a multi-center clinical study on the variability of whole blood viscosity.
Whole blood viscosity has been studied for over thirty years with approximately 1,000 papers published in peer-reviewed journals during that time period. This body of research has correlated whole blood viscosity to numerous disease conditions such as coronary and carotid artery disease as well as every major cardiac risk factor, including blood pressure, LDL cholesterol, C-reactive protein, age, and type-II diabetes.
With respect to this body of published work, Rheologics is responding to a need for establishing standards for healthy ranges for whole blood viscosity and a clearer understanding of the variability of whole blood viscosity in a broad cross-section of patients.
Rheologics' Chairman & Chief Scientific Officer, Kenneth Kensey, MD, said, "This multi-center study will be a vital foundation for future clinical and pharmacological studies that will require reliable standards for healthy whole blood viscosity, findings that have been historically unavailable in a definitive fashion."
About Rheologics Technologies, Inc.
Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at http://www.rheologics.com.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
